Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 4, 2005, Pages 488-494

  McConnell, Michelle S ^a   Byers, Robert H ^b   Frederick, Toni ^c   Peters, Vicki B ^d   Dominguez, Kenneth L ^b   Sukalac, Thom ^b   Greenberg, Alan E ^b   Hsu, Ho Wen ^e   Rakusan, Tamara A ^f,i   Ortiz, Idith R ^g   Melville, Sharon K ^h   Fowler, Mary Glenn ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Los Angeles County Department of Public Health   (United States)

^d NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^e State Laboratory Institute   (United States)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^g UPR School of Medicine   (Puerto Rico)

^h TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

ⁱ GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Antiretroviral therapy; Durability of therapy; Pediatric HIV; Survival trends

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; SEX DIFFERENCE; SURVIVAL RATE; UNITED STATES;

ADOLESCENT; AGE OF ONSET; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; CONTINENTAL POPULATION GROUPS; DRUG THERAPY; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; SURVIVAL ANALYSIS; UNITED STATES;

EID: 20144377456     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000134744.72079.cc     Document Type: Article

References (20)

1. Lindegren ML, Byers RH, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA. 1999;282:531-538.
2. Abrams E, Weedon J, Bertolli J, et al. Aging cohort of perinatally human immunodeficiency virus-infected children in New York City. Pediatr Infect Dis J. 2001;20:511-517.
3. National Institutes of Health. Guidelines for the use of antiretroviral agents in pediatric HIV infection-June 25, 2003. Available at: http://www.aidsinfo.nih.gov/guidelines/. Accessed August 8, 2003.
4. Gortraaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528.
5. de Martino M, Tovo P-A, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA. 2000;284:190-197.
6. Pallela FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
7. Lee LM, Karon JM, Selik R, et al. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA. 2001;285:1308-1315.
8. Moore R, Chaisson R. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13:1933-1942.
9. Palella FJ, Chmiel JS, Moorman AC, et al. Durability and predictors of success of highly active antiretroviral therapy (HAART) for ambulatory HIV-infected patients. AIDS. 2002;16:1617-1626.
10. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 1994;6:1-39.
11. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 2001;13:1-44.
12. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep. 1994;43: 1-10.
13. National Institutes of Health. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents-July 14, 2003. Available at: http://www.aidsinfo.nih.gov/guidelines/. Accessed August 8, 2003.
14. National Institutes of Health. Drugs. Available at: http://www.aidsinfo. nih.gov/. Accessed May 8, 2003.
15. Weidle P, Lichtenstein KA, Moorman AC, et al. Factors associated with the successful modification of antiretroviral therapy. AIDS. 2000;14: 491-497.
16. Stephenson J. New class of anti-HIV drugs. JAMA. 1999;282:1994.
17. De Clerq E. New anti-HIV agents and targets. Med Res Rev. 2002;22:531-565.
18. Riera M, Ribas MA, Perez Elias MJ, et al. Approach to treatment of patients with virologic failure to multiple regimens. Enferm Infecc Microbiol Clin. 2002;20(Suppl 2):58-67.
19. Teglas J, Mayaux M, Blanche S, et al. Antiretroviral therapy and mortality among children with perinatal HIV infection. JAMA. 2000;284:2871-2872.
20. Frederick T, Mascola L, Peters V, et al. Trends in HAART use and immune status among HIV-infected infants and children in the Pediatric Spectrum of Disease project, United States, 1994-2000 [abstract TuPeC4735]. In: Programs and Abstracts of the XIV International Conference on AIDS. Barcelona, July 7-12, 2002.